Akèy › Sistèm Imunitè ak Twoub › Texas › Houston
Etid klinik pou Sistèm Imunitè ak Twoub nan Houston, TX
9 etid pou Sistèm Imunitè ak Twoub ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Ap rekriteFaz 2
- Jade Clinical Site, Houston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Baylor College of Medicine, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Baylor College of Medicine, Houston
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Ap rekriteFaz 3
- Nephro Asso North Illinois Indiana, Houston
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
Ap rekriteFaz 2
- Texas Children's Hospital, Houston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Ap rekriteFaz 1/2
- MD Anderson Texas Medical Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Etid Sistèm Imunitè ak Twoub nan lòt vil
- Washington, DC13 etid
- New York City, NY12 etid
- Boston, MA10 etid
- Philadelphia, PA10 etid
- Atlanta, GA9 etid
- Portland, OR9 etid
- Cleveland, OH8 etid
- Chicago, IL8 etid
- Los Angeles, CA8 etid
- Milwaukee, WI6 etid
- Seattle, WA6 etid
- Cedar Rapids, IA6 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.